Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

MLA

Bekaii-Saab, Tanios S., et al. “Regorafenib Dose-Optimisation in Patients with Refractory Metastatic Colorectal Cancer (ReDOS): A Randomised, Multicentre, Open-Label, Phase 2 Study.” Lancet Oncology, vol. 20, no. 8, Aug. 2019, pp. 1070–82. EBSCOhost, https://doi.org/10.1016/S1470-2045(19)30272-4.

APA

Bekaii-Saab, T. S., Ou, F.-S., Ahn, D. H., Boland, P. M., Ciombor, K. K., Heying, E. N., Dockter, T. J., Jacobs, N. L., Pasche, B. C., Cleary, J. M., Meyers, J. P., Desnoyers, R. J., McCune, J. S., Pedersen, K., Barzi, A., Chiorean, E. G., Sloan, J., Lacouture, M. E., Lenz, H.-J., & Grothey, A. (2019). Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, 20(8), 1070–1082. https://doi.org/10.1016/S1470-2045(19)30272-4

Chicago

Bekaii-Saab, Tanios S, Fang-Shu Ou, Daniel H Ahn, Patrick M Boland, Kristen K Ciombor, Erica N Heying, Travis J Dockter, et al. 2019. “Regorafenib Dose-Optimisation in Patients with Refractory Metastatic Colorectal Cancer (ReDOS): A Randomised, Multicentre, Open-Label, Phase 2 Study.” Lancet Oncology 20 (8): 1070–82. doi:10.1016/S1470-2045(19)30272-4.